Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus Type 1-Infected Children: Analysis of Cellular Immune Responses
- 1 September 2001
- journal article
- Published by American Society for Microbiology in Clinical and Diagnostic Laboratory Immunology
- Vol. 8 (5) , 943-8
- https://doi.org/10.1128/cdli.8.5.943-948.2001
Abstract
The present study analyzes the effect of highly active antiretroviral therapy (HAART) on restoration of cellular immunity in human immunodeficiency virus (HIV)-infected children over a 24-week period following initiation of HAART with ritonavir, nevirapine, and stavudine. The immunological parameters evaluated at four time points (at enrollment and at 4, 12, and 24 weeks of therapy) included cytokine production by monocytes as well as T-cell proliferation in response to mitogen, alloantigen, and recall antigens including HIV type 1 envelope peptides. Circulating levels of interleukin-16 (IL-16) were measured, in addition to CD4+T-cell counts, plasma HIV RNA levels, and the delayed-type hypersensitivity (DTH) response. At enrollment the children exhibited defects in several immune parameters measured. Therapy increased CD4+T-cell counts and decreased viral loads significantly. By contrast, the only immunological parameter that was significantly increased was IL-12 p70 production by monocytes; the DTH response toCandida albicansalso showed a strong increase in patients becoming positive. In conclusion, these results demonstrate that HAART in HIV-infected children affects the dynamics of HIV replication and the CD4+T-cell count over 24 weeks, similar to the pattern seen in HIV-infected adults. Furthermore, these data indicate improvement in antigen-presenting cell immunological function in HIV-infected children induced by HAART.Keywords
This publication has 35 references indexed in Scilit:
- The challenge of immune control of immunodeficiency virusJournal of Clinical Investigation, 1999
- Preliminary Evaluation of Human Immunodeficiency Virus Type 1 (HIV‐1) Immunogen in Children with HIV‐1 InfectionThe Journal of Infectious Diseases, 1999
- Protease inhibitor and triple-drug therapyAIDS, 1998
- Early recovery of CD4+ T lymphocytes in children on highly active antiretroviral therapyAIDS, 1998
- Interleukin-10 Gene Expression Induced by HIV-1 Tat and Rev in the Cells of HIV-1 Infected IndividualsJAIDS Journal of Acquired Immune Deficiency Syndromes, 1996
- Molecular Analysis of Decreased Interleukin-12 Production in Persons Infected with Human Immunodeficiency VirusThe Journal of Infectious Diseases, 1996
- Expression of IL-10, IL-4 and interferon-gamma in unstimulated and mitogen-stimulated peripheral blood lymphocytes from HIV-seropositive patientsClinical and Experimental Immunology, 1995
- Impaired interleukin 12 production in human immunodeficiency virus-infected patients.The Journal of Experimental Medicine, 1994
- Interleukin-2 production used to detect antigenic peptide recognition by T-helper lymphocytes from asymptomatic HIV-seropositive individualsNature, 1989
- Immunological abnormalities in human immunodeficiency virus (HIV)-infected asymptomatic homosexual men. HIV affects the immune system before CD4+ T helper cell depletion occurs.Journal of Clinical Investigation, 1988